Follistatin 344

What Is Follistatin 344?

Follistatin (FST) 344 is a synthetic version of the naturally occurring human follistatin protein. Follistatin is found in nearly all tissues of higher animals and comes in two separate isoforms as a result of alternative gene splicing. Its primary biological function is neutralization of proteins in the TGF-beta superfamily. It has particularly potent neutralizing effects on activin, myostatin, and follicle-stimulating hormone.

Source: NCBI Gene

Follistatin 344 Structure

Source: Uniprot

Sequence: MVRARHQPGG LCLLLLLLCQ FMEDRSAQAG NCWLRQAKNG RCQVLYKTEL SKEECCSTGR LSTSWTEEDV NDNTLFKWMI FNGGAPNCIP CKETCENVDC GPGKKCRMNK KNKPRCVCAP DCSNITWKGP VCGLDGKTYR NECALLKARC KEQPELEVQY QGRCKKTCRD VFCPGSSTCV VDQTNNAYCV TCNRICPEPA SSEQYLCGND GVTYSSACHL RKATCLLGRS IGLAYEGKCI KAKSCEDIQC TGGKKCLWDF KVGRGRCSLC DELCPDSKSD EPVCASDNAT YASECAMKEA ACSSGVLLEV KHSGSCNSIS EDTEEEEEDE DQDYSFPISS ILEW
Molecular Weight: 3780 g/mol
PubChem CID: 178101631
Synonyms: Activin-Binding Protein, FSH-Suppressing Protein, FST

Follistatin 344 Effects

Follistatin Research and Muscle Growth

Myostatin is a protein produced by muscle cells themselves that inhibits muscle cell growth and differentiation. It is a member of the TGF-beta protein family and therefore is susceptible to inhibition by follistatin. Previous research has shown that animals lacking myostatin have significantly more muscle mass and are stronger than normal. This led scientists to speculate that administration of follistatin could improve muscle growth and help to treat a number of medical conditions, like muscular dystrophy, that impact muscle growth and strength.

In mouse models, follistatin has been shown to increase lean muscle mass without the need for special dietary or exercise requirements. After just eight weeks of follistatin injections, mice in the treatment group had 10% more muscle mass than mice in the control group^[1]. This, again, is a result obtained without exercising the mice or subjecting them to special diets, indicating that gains could be even more substantial with appropriate training.

Research in everything from mice to monkeys has shown increased muscle size and strength when follistatin therapy is initiated. There is hope that the protein can be used to treat muscle disorders, such as inclusion body myositis, that have so far proved relatively resistant to pharmacologic intervention^[2]. Research in mouse models of Duchenne muscle dystrophy (DMD), for instance, show that follistatin treatment leads to hypertrophy of skeletal muscle while also reducing inflammation and fibrosis. The benefits are dose-dependent and lead to clinically relevant changes in strength in the setting of DMD^[3]. These are significant findings that could help doctors to reduce or eliminate the weakness associated with certain muscle disorders, thereby restoring quality of life and reducing morbidity in these conditions.

One interesting aspect of research into the effects of follistatin on muscle growth has found that gene administration of follistatin at any age can lead to long-term benefits on muscle hypertrophy. In mouse models, one-time administration of follistatin via gene therapy has led to more than two years of enhanced mass and strength in both normal and dystrophic animals. These benefits were observed regardless of the age of the animal at the time of gene therapy^[4].

Research indicates that follistatin boosts muscle growth by stimulating the insulin/IGF-1 pathway. Interestingly, the protein only requires that one of these signaling molecules be present for full anabolic effect. Follistatin actually causes a decrease in muscle expression of IGF-1, something that was initially counter-intuitive to scientists until they understood that its effects can also be mediated via insulin itself^[5]. Research indicates that follistatin influences the pancreas to produce more insulin, suggesting that the protein is intimately associated with insulin signaling.

Changes in strength as a result of follistatin (FS) treatment.
Source: PubMed

Follistatin May Improve Survival in Breast Cancer

The presence of follistatin in breast tumors was examined in a clinical study using reverse transcription polymerase chain reaction (RT-PCR) as well as immune-histochemistry techniques. It was found that follistatin is under-expressed in breast cancer for the most part, but is over-expressed in a small proportion of cases. In the cases where follistatin is over-expressed, tumors grow faster but are less invasive^[6]. The presence of follistatin correlates strongly with survival and reduce breast cancer metastasis.

The ability of follistatin to suppress metastasis was confirmed using a mouse model of HER2-positive breast cancer. It was found that follistatin blocks activin-induced migration of breast epithelial cells, but the protein is lacking in the average breast tumor. Restoring follistatin was found to completely block the formation of lung metastases even though it had no impact on tumor growth^[7].

Follistatin plays a role in benign proliferative disorders of the breast as well. Conditions like fibroadenoma, florid hyperplasia without atypia, ductal carcinoma in situ, and more are all characterized by increased levels of FST. Once again, the trend is toward follistatin boosting local growth while reducing the probability of distant metastasis^[8].

Probability of breast cancer recurrence in the brain or lung in low versus high follistatin (FST) environments.
Source: PubMed

Follistatin in Esophageal Cancer

Research has identified bone morphogenic protein (BMP) as a causative agent in the transition of normal esophageal tissue to Barrett’s esophagus, a precursor to cancer. It appears that acid reflux over-activates BMP in the esophagus and that counteracting this over-activation, such as through follistatin supplementation, could prevent the development of Barrett’s esophagus in the first place.

BMP misregulation is actually a common theme in a number of different cancers. For instance, impaired BMP signaling is important in the progression of colon cancer. More research clearly needs to be done, particularly in animal models, to better quantify how follistatin can be used in the treatment and prevention of BMP misregulation.

Follistatin Research and Cancer Treatment

Researchers have found that follistatin active in a number of different tumors and that its effects are not just limited to breast cancer and liver carcinoma. With better understanding of how follistatin works, it is hoped that a number of clinical applications for the protein can be developed. Currently, follistatin expression has been associated with improved survival in breast cancer, but shortened survival in lung, ovarian, and gastric cancers. It is hoped that understanding these differences in how the protein affects survival will allow for the development of treatment adjuvant tailored to specific types of cancer. Follistatin research may even form the basis of a cancer preventative or vaccine, slowing rates of metastasis and improving long-term survival^[9].

Follistatin Associated with Cell Proliferation

The research into breast cancer revealed an odd dichotomy in that follistatin promotes cell proliferation but restricts metastasis. As it turns out, this dichotomy of follistatin is true in most tissues. In the liver, in particular, hepatocytes require follistatin expression in order to proliferate. Rat models show that the inactivation of activin via follistatin may be necessary for proliferation to take place^[10]. This may explain why follistatin is associated with increased tumor growth, but decreased tumor invasion and metastasis. There is likely an energy trade off that takes place during growth in which the migratory functions of a cell are shut off in order to shunt energy into growth and reproduction.

Follistatin Research and Liver Protection

Follistatin has been shown to protect the liver against the earliest phases of fibrosis and thus slow progression of liver disease. Research in rats shows a 32% reduction in fibrosis after four weeks of follistatin treatment, a positive trait attributed to an 87% reduction in hepatocyte death in treatment groups^[11]>. Dysregulation of follistatin has been linked to the progression of fibrosis to cancer in the liver^[12].

Follistatin Provides Insight into Congenital Blindness

The ability of the optic nerve to fuse in early development is critical to ability of humans to see. It has been known for some time that TGF-beta signaling is critical to remodeling of the extracellular matrix and eventual fusion of the optic nerve. Research suggests that high levels of TGF-beta proteins, particularly bone morphogenic protein (BMP), suppress optic fusion and can lead to blindness. Inhibition of these proteins can override their effect and lead to fusion, thereby ensuring the optic nerve is intact and thus vastly reducing risk of blindness^[13]. There is basic research into the benefits of follistatin supplementation during critical development periods of pregnancy to ensure that optic nerve fusion takes place.

Follistatin Research and Hair Growth

Research in humans indicates that follistatin, particularly when used in combination with other hair-growth stimulants, can improve hair growth substantially. Measurements in a small trial of 26 individuals showed a 20% increase in hair density and a nearly 13% increase in overall thickness. These results remained for at least one year following treatment with a single intradermal injection of a follistatin/Wnt- complex^[14].

Follistatin Research and Insulin Deficiency and Diabetes

Research in mice indicates that over-expression of follistatin can actually increase the mass of beta-islet cells, the cells responsible for producing insulin. This leads to an improvement in insulin levels, decreased fasting glucose levels, and a decrease in the symptoms of diabetes. Most importantly, mice treated with follistatin doubled their lifespans as the complications of diabetes were virtually eliminated^[15]. There is hope that follistatin may shed some light on how to improve both type 1 and type 2 diabetes by boosting the function of whatever functional islet cells are left in the pancreas. This approach is similar to using exogenous insulin to treat diabetes, but benefits from being subject to all of the normal physiologic controls that regulate normal insulin release. With improved physiologic dosing of insulin comes improved outcomes in diabetes.

The Future of Follistatin Research

Follistatin research touches a number of human conditions from cancer and muscle dysfunction to hair growth and diabetes. The field is very active, with new research published frequently and new insight into the complex physiology of follistatin being gained regularly. There is a great deal of potential in follistatin research, including the potential to develop therapies for a variety of diseases as well as an ability to probe deeper into human physiology.

Follistatin 344 exhibits moderate side effects, low oral and excellent subcutaneous bioavailability in mice. Per kg dosage in mice does not scale to humans. Follistatin 344 for sale at Peptide Sciences is limited to educational and scientific research only, not for human consumption. Only buy Follistatin 344 if you are a licensed researcher.

Article Author

The above literature was researched, edited and organized by Dr. Logan, M.D. Dr. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.

Scientific Journal Author

Ruth A. Keri, PhD. Professor and Vice Chair at Department of Pharmacology in Case Western University School of Medicine. Dr. Keri is an Associate Director for Basic Research, Case Comprehensive Cancer Center. For more than 17 years, her research has focused on the genomic and signaling mechanisms that control mammary gland development and cancer. This has involved generating and using data from cell lines and genetically manipulated mouse models of breast cancer as well as evaluation of publicly available human breast cancer array data. She has designed and used mouse models of disease throughout her research career, including assessing the efficacy of therapeutic agents such as vitamin D analogs, rapamycin, and dasatinib in mammary cancer models. Most specifically, she studied Follistatin’s effect of suppressing metastatis in a mouse model of HER2-positive breast cancer. She also has significant experience assessing drug synergy, in vitro and in vivo. Her laboratory extensively uses xenograft models of breast cancer. They also have expertise in the analysis of proliferation and apoptosis, migration and invasion, centrosome defects and genomic instability, and gene-specific chromatin immunoprecipitation as well as immunohistochemistry of mouse and human tissues. Underscoring this ability, she was the co-leader of the Breast Cancer Program-in-Development in the Case Comprehensive Cancer Center (Case CCC) before becoming its Associate Director for Basic Research. Moreover, she has significant expertise in Pharmacology, having earned my doctoral in this field. She was recently awarded the Garvin and Frackelton Professor of Cancer Research at CWRU.

Ruth A. Keri, PhD. is being referenced as one of the leading scientists involved in the research and development of Follistatin 344. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Peptide Sciences and this doctor. The purpose of citing the doctor is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying this peptide. Dr. Keri is listed in [7] under the referenced citations.

Referenced Citations

1. C. Schumann et al., “Increasing lean muscle mass in mice via nanoparticle-mediated hepatic delivery of follistatin mRNA,” Theranostics, vol. 8, no. 19, pp. 5276–5288, Oct. 2018.
2. L. R. Rodino-Klapac, A. M. Haidet, J. Kota, C. Handy, B. K. Kaspar, and J. R. Mendell, “Inhibition of myostatin with emphasis on follistatin as a therapy for muscle disease,” Muscle Nerve, vol. 39, no. 3, pp. 283–296, Mar. 2009.
3. A. Iskenderian et al., “Myostatin and activin blockade by engineered follistatin results in hypertrophy and improves dystrophic pathology in mdx mouse more than myostatin blockade alone,” Skelet. Muscle, vol. 8, Oct. 2018.
4. A. M. Haidet et al., “Long-term enhancement of skeletal muscle mass and strength by single gene administration of myostatin inhibitors,” Proc. Natl. Acad. Sci. U. S. A., vol. 105, no. 11, pp. 4318–4322, Mar. 2008.
5. C. Barbé et al., “Role of IGF-I in follistatin-induced skeletal muscle hypertrophy,” Am. J. Physiol. – Endocrinol. Metab., vol. 309, no. 6, pp. E557–E567, Sep. 2015.
6. C. Zabkiewicz, J. Resaul, R. Hargest, W. G. Jiang, and L. Ye, “Increased Expression of Follistatin in Breast Cancer Reduces Invasiveness and Clinically Correlates with Better Survival,” Cancer Genomics Proteomics, vol. 14, no. 4, pp. 241–251, Aug. 2017.
7. D. D. Seachrist, S. T. Sizemore, E. Johnson, F. W. Abdul-Karim, K. L. Weber Bonk, and R. A. Keri, “Follistatin is a metastasis suppressor in a mouse model of HER2-positive breast cancer,” Breast Cancer Res. BCR, vol. 19, no. 1, p. 66, 05 2017.
8. E. Bloise et al., “Differential expression of follistatin and FLRG in human breast proliferative disorders,” BMC Cancer, vol. 9, p. 320, Sep. 2009.
9. L. SHI, J. RESAUL, S. OWEN, L. YE, and W. G. JIANG, “Clinical and Therapeutic Implications of Follistatin in Solid Tumours,” Cancer Genomics Proteomics, vol. 13, no. 6, pp. 425–436, Oct. 2016.
10. H. Ooe et al., “Proliferation of rat small hepatocytes requires follistatin expression,” J. Cell. Physiol., vol. 227, no. 6, pp. 2363–2370, Jun. 2012.
11. S. Patella, D. J. Phillips, J. Tchongue, D. M. de Kretser, and W. Sievert, “Follistatin attenuates early liver fibrosis: effects on hepatic stellate cell activation and hepatocyte apoptosis,” Am. J. Physiol. Gastrointest. Liver Physiol., vol. 290, no. 1, pp. G137-144, Jan. 2006.
12. M. Grusch et al., “Deregulation of the activin/follistatin system in hepatocarcinogenesis,” J. Hepatol., vol. 45, no. 5, pp. 673–680, Nov. 2006.
13. M. D. Knickmeyer et al., “TGFβ-facilitated optic fissure fusion and the role of bone morphogenetic protein antagonism,” Open Biol., vol. 8, no. 3, 2018.
14. M. P. Zimber et al., “Hair regrowth following a Wnt- and follistatin containing treatment: safety and efficacy in a first-in-man phase 1 clinical trial,” J. Drugs Dermatol. JDD, vol. 10, no. 11, pp. 1308–1312, Nov. 2011.
15. C. Zhao et al., “Overcoming Insulin Insufficiency by Forced Follistatin Expression in β-cells of db/db Mice,” Mol. Ther., vol. 23, no. 5, pp. 866–874, May 2015.

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATONAL AND EDUCATIONAL PURPOSES ONLY.

The products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: in glass) are performed outside of the body.  These products are not medicines or drugs and have not been approved by the FDA to prevent, treat or cure any medical condition, ailment or disease.  Bodily introduction of any kind into humans or animals is strictly forbidden by law.